Jerusalem, G., Farah, S., Abdi, E., Kamby, C., Thompson, A., Loibl, S., Gavilá, J., Kuroi, K., Marth, C., Müller, B., O'Reilly, S., Gombos, A., Courtois, A., Ruhstaller, T., Burstein, HJ, Rabaglio, M., Ruepp, B, Ribi, K, Viale, G, Gelber, RD, Coates, AS, Loi, S, Goldhirsch, A, Chirgwin, J., Regan, MM, Colleoni, M, Aebi, S., Karlsson, P., Neven, P., Hitre, E., Graas, M. P., Simoncini, E.. Elsevier; 2021. Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

Rabaglio, M., Sun, Z., Colleoni, M., Pienkowski, T., Nogaret, J. -M., Láng, I., Smith, I., Gelber, R. D., Goldhirsch, A., Coates, A. S., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J.. Oxford University Press; 2009. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

Huober, J., Cole, B. F., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D., Thürlimann, B., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I.. Springer; 2014. Symptoms of endocrine treatment and outcome in the BIG 1-98 study.